Cart
sales@molnova.com
Merodantoin
CAS No. 143413-73-4
Merodantoin( —— )
Catalog No. M27994 CAS No. 143413-73-4
Merodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 133 | In Stock |
|
| 5MG | 149 | In Stock |
|
| 10MG | 220 | In Stock |
|
| 25MG | 337 | In Stock |
|
| 50MG | 462 | In Stock |
|
| 100MG | 619 | In Stock |
|
| 200MG | 835 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMerodantoin
-
NoteResearch use only, not for human use.
-
Brief DescriptionMerodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.
-
DescriptionMerodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
Recptorcereblon (CRBN) E3 ligase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number143413-73-4
-
Formula Weight242.34
-
Molecular FormulaC11H18N2O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCCCCN1C(=O)C(=O)N(CCCC)C1=S
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.
molnova catalog
related products
-
1-[2,4-Dihydroxy-6-m...
Xanthohumol, prenylchacone flavonoid, is a natural product with multi-biofunctions purified from Hops Humulus lupulus. Xanthohumol is effective against HIV-1 and might serve as an interesting lead compound. It may represent a novel chemotherapeutic agent for HIV-1 infection.
-
Anticancer agent 110
Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations.
-
RAPTA-C
RAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.
